Yazar "Tuzcu, A. K." seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    Angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in Turkish patients
    (Springer, 2013) Simsek, S.; Tekes, S.; Turkyilmaz, A.; Tuzcu, A. K.; Kilic, F.; Culcu, N. N.; Isik, B.
    Background: The ACE gene has received substantial attention in recent years as candidate for a variety of diseases. The most common polymorphism in ACE gene is the Insertion/Deletion (I/D, rs4646994) polymorphism located on intron 16. Aim: We investigated the association between metabolic syndrome (MS) and the insertion (I) -deletion (D) polymorphisms in the angiotensin converting enzyme (ACE) gene in south-east of Turkey. Subjects and methods: One hundred and sixty subjects, with 101 cases of MS and 59 age-and gender-matched healthy controls were included in the study. Results: The frequency of ACE I/D polymorphism was found to be 49.5% for DD, 36.6% for ID, and 13.9% for II in the MSstudy group and 44.1% for DD, 42.4% for ID and 13.5% for II in the control group. Allele frequencies were found to be 0.68% for D and 0.32% for I allele in the study group with MS and 0.65% for D, 0.35% for I allele in the control group. The I/D polymorphism of the ACE gene, DD, ID, and II genotypes occurred with similar frequencies in the study group with MS and the control group with no significant differences (p > 0.05). On applying one-way analysis of variance to different ACE gene polymorphic groups in patients with MS were not significantly associated to ACE gene polymorphism and waist circumference, systolic blood pressure, diastolic blood pressure, fasting blood glucose, HDL, and LDL (p > 0.05). Conclusions: Further studies of patients in larger numbers and of different ethnic backgrounds may be necessary to elucidate the association between the ACE I/D gene polymorphism and MS.
  • [ X ]
    Öğe
    BAD BONE AND HIGH SCLEROSTIN IN NON-FUNCTIONING PITUITARY ADENOMA: IS IT REALLY NON-FUNCTIONING?
    (Springer, 2022) Pekkolay, Z.; Yildirim, D. Varhan; Tuzcu, S. Altun; Tasdemir, B.; Tuzcu, A. K.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Baseline and stimulated thyroid functions in Behcet's disease
    (Blackwell Publishing, 2006) Akdeniz, S.; Colak, S.; Tuzcu, A. K.; Bahceci, M.; Harman, M.
    [Abstract Not Available]
  • [ X ]
    Öğe
    A simple way to estimate mean plasma glucose and to identify Type 2 diabetic subjects with poor glycaemic control when a standardized HbA1c assay is not available
    (Wiley, 2006) Ozmen, S.; Cil, T.; Atay, A. E.; Tuzcu, A. K.; Bahceci, M.
    Aims To evaluate the relationship between HbA(1c) and fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels, and to estimate the mean plasma glucose (mPG) derived from FPG and PPG that would predict Type 2 diabetic subjects with poor glycaemic control. Methods FPG, PPG and HbA(1c) values from 565 Type 2 diabetic patients (247 men and 318 women) were recorded. Linear regression analysis and Pearson's correlation was used to determine the relationship between HbA(1c), FPG and PPG. FPG and PPG were included as explanatory variables of HbA(1c) in linear regression analysis. Results The American Diabetes Association's objective of achieving an HbA(1c) level < 7.0% was obtained in 26.2% of the patients. The coefficients of FPG and PPG which determined HbA(1c) were similar. Therefore, mPG was calculated using the equation (FPG + PPG)/2. Pearson's correlation coefficient for HbA(1c) and FPG, PPG and mPG were 0.723 (P < 0.0001), 0.734 and 0.761 (P < 0.0001), respectively. A mPG cut-off value of 10 mmol/l predicted an HbA(1c) > 7% in the whole population, with a sensitivity of 84.2% and specificity of 80.4%. The area was high (0.90) in receiver-operating characteristic (ROC) curve analysis performed to examine the performance of mPG to predict HbA(1c) > 7%. Conclusions The mPG derived from FPG and PPG correlates strongly with HbA(1c). We therefore suggest that using a cut-off of 10 mmol/l for mPG may be appropriate in diabetes management in the primary-care setting, where most management of Type 2 diabetes occurs.